Ipamorelin Dosing Regimens Studied Clinically
Ipamorelin is a growth hormone secretagogue studied primarily in investigational clinical settings rather than with an FDA-approved, labeled dosing regimen for routine use. [1]
Postoperative Ileus After Bowel Resection Dosing Regimen
In a phase 2 proof-of-concept trial for postoperative ileus management after bowel resection, ipamorelin was administered as intravenous infusions at 0.03 mg/kg twice daily. [2]
Dosing was started on postoperative day (POD) 1 and continued until POD 7 or hospital discharge, whichever occurred first. [2]
Clinical Benefits Observed in Postoperative Ileus Trials
The primary endpoint was time from first dose to first tolerated meal without nausea or vomiting. [1]
The median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p = 0.15). [2]
Secondary and additional endpoints did not show differences between ipamorelin and placebo in that trial. [1]
Safety Outcomes Relevant to Benefit-Risk Interpretation
In the same evidence base summarized by FDA, adverse events included hypokalemia (reported 12.5% with ipamorelin vs 3.4% with placebo), insomnia (10.7% vs 5.2%), and hyperglycemia at discharge (14.3% vs 8.6%). [1]
Evidence Limitations for “Recommended” Dosing
No clinical evidence establishes ipamorelin dosing as a standard recommended regimen for growth hormone deficiency or other chronic indications. [1]
The dosing regimen above reflects the studied protocol for postoperative ileus rather than an established population-wide dosing recommendation. [1]